KLF6-based IA diagnosis and treatment method
Through KLF6-based screening methods, drugs and models for intracranial aneurysms were developed, and the problem of lack of effective drug treatment in the prior art was solved, accurate diagnosis and treatment of IA was achieved, and surgical trauma and economic burden were reduced.
Patent Information
- Application Number
- CN202410935551.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-15
AI Technical Summary
No effective drug treatment has been found in the existing treatment methods for intracranial aneurysms (IA), which leads to high trauma and heavy financial burden. Especially for patients with high surgical risks, it is urgent to develop non-invasive drug treatments to prevent IA. progress and rupture.
Through KLF6-based screening methods, core genes and drugs related to KLF6 are obtained, and candidates for predicting IA risks and treatment of IA include the use of MLT as a promoter or inhibitor of KLF6, regulating the immune microenvironment and inhibiting the blood vessel walls. Cell apoptosis, thereby constructing an IA model and preparing therapeutic drug compositions.
A new strategy is provided for the treatment and diagnosis of IA, a new strategy is provided for IA treatment through the KLF6 screening method, a model with high diagnostic efficacy is constructed, and further treatment of diseases by regulating the immune microenvironment, reducing the Tumor rate and inflammatory response of IA.
Smart Images

Figure CN118969180A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a method for diagnosing and treating IA based on KLF6. Background Art
[0002] Intracranial aneurysm (IA) is a cerebrovascular disease with unknown etiology and high mortality and disability rates. Currently, surgery and endovascular interventional treatment of IA are recognized treatments, and effective therapeutic drugs have not yet been found. In order to reduce surgical trauma and reduce the economic burden of patients, especially for IA patients with higher surgical risks, it is urgent to develop non-invasive drug treatment methods to prevent the progression and rupture of IA. In-depth exploration of the molecular mechanisms of the occurrence and development of IA and the development of drug treatments are particularly important for preventing the formation of IA and reducing the risk of IA rupture. Summary of the invention
[0003] To remedy the deficiencies of the prior art, the present invention provides a method, system and device for developing drugs for preventing and treating IA, as well as drugs discovered based on the method and applications of the drugs.
[0004] The present invention provides a method, system and device for predicting IA risk.
[0005] To achieve the above object, the present invention adopts the following technical solution:
[0006] The first aspect of the present invention provides a method for screening candidate drugs for treating IA based on KLF6, the method comprising:
[0007] Get the core genes related to KLF6,
[0008] Obtain drugs related to core genes related to KLF6, wherein the drugs are candidate drugs for treating IA.
[0009] A second aspect of the present invention provides a method for predicting IA risk based on KLF6, the method comprising:
[0010] Obtaining KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16;
[0011] The gene expression data is input into a classifier, and a classification result of IA risk is output.
[0012] A third aspect of the present invention provides a computer-readable storage medium,
[0013] It stores a program, and the program executes the method described in the first aspect of the present invention; or
[0014] It stores a program, and the program executes the method described in the second aspect of the present invention.
[0015] A fourth aspect of the present invention provides a system, comprising:
[0016] Acquisition unit: Acquisition of KLF6-related core genes;
[0017] Analysis unit: Analysis of drugs related to core genes associated with KLF6;
[0018] Output unit: output candidate drugs for treating IA; or
[0019] Acquisition unit: acquiring KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16;
[0020] Analysis unit: Analyze the risks of IA;
[0021] Output unit: outputs the classification results of IA risks.
[0022] A fifth aspect of the present invention provides an electronic device, comprising:
[0023] A memory, a processor and a computer program stored in the memory; the processor executes the computer program to implement the method according to the first aspect of the present invention; or
[0024] A memory, a processor and a computer program stored in the memory; the processor executes the computer program to implement the method described in the second aspect of the present invention.
[0025] The sixth aspect of the present invention provides a method for constructing an IA model, which comprises administering a promoter of KLF6.
[0026] The seventh aspect of the present invention provides an IA model constructed by the method described in the sixth aspect of the present invention.
[0027] The eighth aspect of the present invention provides a method for regulating the immune microenvironment, which comprises administering a KLF6 regulating agent or administering MLT.
[0028] The ninth aspect of the present invention provides a method for regulating the expression level of KLF6, which comprises administering MLT.
[0029] The tenth aspect of the present invention provides a method for inhibiting apoptosis of vascular wall cells, comprising administering MLT or a specific inhibitor of KLF6.
[0030] The eleventh aspect of the present invention provides a method for inhibiting inflammation, comprising administering MLT or a specific inhibitor of KLF6.
[0031] A twelfth aspect of the present invention provides a method for promoting inflammation, comprising administering a promoter of KLF6.
[0032] The thirteenth aspect of the present invention provides the use of a reagent for detecting a biomarker in the preparation of a product for diagnosing IA, wherein the biomarker is selected from one or more of NEDD9, NPTX1, PTP4A1, and DUSP16.
[0033] A fourteenth aspect of the present invention provides the use of KLF6 in the preparation of a pharmaceutical composition for treating IA, wherein the pharmaceutical composition comprises an inhibitor of KLF6.
[0034] A fifteenth aspect of the present invention provides use of MLT in preparing a pharmaceutical composition for treating IA.
[0035] Advantages and beneficial effects of the present invention:
[0036] Central venous hepatocytes are key mediators of the interaction between Collinsella and hypercholesterolemia. Based on this, the present invention provides a method, system, device and computer-readable storage medium for screening cholesterol-lowering drugs based on Collinsella and central venous hepatocytes. The present invention provides an efficient, accurate and rapid screening method for the research and development of new cholesterol-lowering drugs, and has a very broad application prospect in the screening of new cholesterol-lowering drugs.
[0037] The present invention provides a method for screening drugs based on KLF6, and provides a new strategy for the treatment of IA.
[0038] The present invention provides a method for constructing a model for predicting IA based on KLF6 and a model constructed using the method. The model has high diagnostic efficacy and provides a new means for accurate diagnosis of IA.
[0039] The present invention provides a method for regulating an immune microenvironment based on KLF6 and a KLF6-acting drug MLT and a method for regulating KLF6, providing a new method for further treating diseases by regulating the immune microenvironment. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 This is a flow chart of a method for screening drugs for treating IA based on KLF6 provided in an embodiment of the present invention;
[0041] Figure 2 It is a flow chart of a method for predicting IA risk based on KLF6 provided in an embodiment of the present invention;
[0042] Figure 3The following are the analysis results of KLF6, where A is the expression and ROC curve of KLF6 in the training set, and B is the expression and ROC curve of KLF6 in the validation set;
[0043] Figure 4 are ROC curves of different classification models, where A is the ROC curve of the SVM model in the training set; B is the ROC curve of the RF model in the training set; C is the ROC curve of the SVM model in the validation set; D is the ROC curve of the RF model in the validation set;
[0044] Figure 5 This is a graph showing the mRNA detection results of KLF6 in IA patients;
[0045] Figure 6 1 is a graph showing the test results of serum ET-1 and vWF protein, wherein A is a graph showing the test results of ET-1; B is a graph showing the test results of vWF protein;
[0046] Figure 7 : is the test result diagram of serum KLF6 protein, wherein A is the electrophoresis diagram; B is the statistical diagram of KLF6 protein expression;
[0047] Figure 8 This is a graph of the mRNA detection results of KLF6;
[0048] Fig. 9 : is the detection result diagram of KLF6 protein, wherein A is the electrophoresis diagram; B is the statistical diagram of KLF6 protein expression;
[0049] Fig.10 : are cell proliferation test result diagrams, wherein A is the MTT test result diagram, and B is the clone formation test result diagram;
[0050] Fig.11 is the result of cell apoptosis detection;
[0051] Fig.12 is the result diagram of apoptosis factor detection, wherein A is the electrophoresis diagram, B, C, and D are the detection result diagrams of Bcl-2, Bax, and cleaved caspase-3, respectively;
[0052] Fig.13 Flow cytometry was used to detect monocytes (CD14 + HLA-DR + ), Treg cells (CD4 + FOXP3 + ), wherein A is a statistical graph of monocytes; B is a statistical graph of Treg cells;
[0053] Fig.14 This is the result chart of inflammatory factor detection;
[0054] Fig.15 This is the result of HE staining;
[0055] Fig.16 It is the statistical result diagram of TUNEL staining to detect cell apoptosis;
[0056] Fig.17 This is a graph of the mRNA detection results of KLF6;
[0057] Fig.18 This is a picture of the immunohistochemical test results;
[0058] Fig.19 This is a graph showing the detection results of apoptosis factors;
[0059] Fig. 20 This is the test result diagram of inflammatory factors;
[0060] Fig.21 Flow cytometry was used to detect monocytes (CD14 + HLA-DR + ), Treg cells (CD4 + FOXP3 + ), where A is a statistical chart of monocytes; B is a statistical chart of Treg cells. DETAILED DESCRIPTION
[0061] The invention will be further described below in conjunction with specific examples. It should be understood that the specific embodiments described herein are presented by way of example and are not intended to limit the invention. The main features of the invention may be used in a variety of embodiments without departing from the scope of the invention.
[0062] Figure 1 : is a schematic flow chart of a method for screening candidate drugs for treating IA based on KLF6 provided by an embodiment of the present invention. Specifically, the method comprises the following steps:
[0063] S101: Obtaining KLF6-related core genes;
[0064] In one embodiment, the method for determining the core genes comprises:
[0065] Obtain sample sequencing data;
[0066] The KLF6 expression data of IA samples were obtained from the sequencing data, and the samples were divided into two groups based on the expression of KLF6: KLF6 high expression group and KLF6 low expression group;
[0067] Obtain differentially expressed genes between the KLF6 high expression group and the KLF6 low expression group;
[0068] Co-expression network analysis was performed on the sequencing data of IA samples, and the KLF6 high expression group and KLF6 low expression group were extracted as phenotypic data to screen the hub module;
[0069] Genes in the hub module were extracted, and key genes were screened based on module connectivity and KLF6 high-low grouping relationships;
[0070] The key genes and the differentially expressed genes in the KLF6 high expression group and the KLF6 low expression group were extracted, and the core genes were screened. The core genes were the intersection genes of the key genes and the differentially expressed genes in the KLF6 high expression group and the KLF6 low expression group.
[0071] In one embodiment, WGCNA is used to perform co-expression network analysis on sequencing data of IA samples.
[0072] In one embodiment, the training set IA sample data is clustered using the average linkage method in the "hclust" function of WGCNA to detect and remove outliers. Then, the "pickSoftThreshold" function is used to select a suitable soft threshold to construct a scale-free topology. Then, the adjacency matrix is calculated based on the kernel value, and the adjacency matrix is converted into a topological overlap matrix (Topological overlap matrix, TOM) and a corresponding dissimilarity matrix (1-TOM). Genes with similar expression patterns are clustered together, and modules are divided according to the "cutreeDynamic" function with default parameters, and merged based on the similarity of the modules.
[0073] In a specific embodiment, the training set IA sample data is clustered using the average linkage method in the "hclust" function of WGCNA to detect outliers. 70 is selected as the height of the cut tree to remove outliers. Then, the "pickSoftThreshold" function is used to select a suitable soft threshold (β=6) to construct a scale-free topology, the height is set to 0.90, and the minimum number of genes in the module is set to 150. Then, the adjacency matrix is calculated based on the kernel value, and the adjacency matrix is converted into a topological overlap matrix (Topological overlap matrix, TOM) and a corresponding dissimilarity matrix (1-TOM). Genes with similar expression patterns are clustered together, and the modules are divided according to the "cutreeDynamic" function with default parameters, and they are truncated at a height of 0.25 to merge the modules.
[0074] In one embodiment, the conditions for screening key genes based on module connectivity and KLF6 high and low grouping relationship are |MM|>0.6 and |GS|>0.4, where |MM| refers to the absolute value of the Pearson correlation between genes, and |GS| is the absolute value of the Pearson correlation between each gene and the KLF6 high and low groups.
[0075] S102: Obtain drugs related to core genes related to KLF6, where the drugs are candidate drugs for treating IA.
[0076] In one embodiment, drug database data is obtained to obtain drugs associated with core genes associated with KLF6.
[0077] In one embodiment, the drug database is selected from DGIdb.
[0078] In one embodiment, the method for screening drugs for treating IA based on KLF6 further comprises molecular docking of drugs related to core genes related to KLF6 and proteins encoded by core genes related to KLF6.
[0079] In one embodiment, prior to molecular docking, the protein and drug molecules are subjected to hydrogenation and other pre-processing using AutoDock Tools.
[0080] In one embodiment, the three-dimensional structure file of the target protein (core gene encoded protein) as the receptor and the three-dimensional structure file of the drug are obtained, and the protein and drug molecules are hydrogenated and otherwise preprocessed using AutoDock Tools to perform molecular docking calculations.
[0081] In one embodiment, drug molecules with better binding activity are screened. In one embodiment, when the binding energy is less than -5.0 kJ / mo, the drug molecule has better binding activity.
[0082] In one embodiment, the screened drugs include melatonin (MLT).
[0083] In one embodiment, the method for screening a drug for treating IA based on KLF6 comprises:
[0084] S101: Obtain KLF6-related core genes KLF6, ZBTB21, GPRC5A, NEDD9, DUSP5, NFIL3, ITPRIP, ABL2, C8orf4, EIF2AK3, EMP1, PTP4A1, EIF4A3, MYC, UAP1, RCAN1, UGCG, TRIB1, SLC41A1, XIRP1, CD70, and NPTX1;
[0085] S102: Obtain drugs related to core genes related to KLF6, where the drugs are candidate drugs for treating IA.
[0086] Figure 2 1 is a flow chart of a method for predicting IA risk based on KLF6 provided by an embodiment of the present invention. Specifically, the method comprises the following steps:
[0087] S101: Obtaining KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16;
[0088] S102: inputting the gene expression data into a classifier, and outputting a classification result of IA risk;
[0089] In one embodiment, the method for constructing a classifier comprises:
[0090] Obtaining expression data of subject samples;
[0091] The KLF6 expression data of IA samples were obtained from the expression data, and the samples were divided into two groups based on the expression level of KLF6: KLF6 high expression group and KLF6 low expression group;
[0092] Obtain differentially expressed genes between the KLF6 high expression group and the KLF6 low expression group;
[0093] Co-expression network analysis was performed on the transcriptome data of IA samples, and the KLF6 high expression group and KLF6 low expression group were extracted as phenotypic data to screen the hub module;
[0094] Genes in the hub module were extracted, and key genes were screened based on module connectivity and KLF6 high and low grouping relationships.
[0095] Extract key genes and differentially expressed genes in the KLF6 high expression group and KLF6 low expression group, and screen core genes;
[0096] Regression analysis was performed on the core genes to screen characteristic genes and construct a classifier for predicting IA risk.
[0097] In one embodiment, LASSO regression analysis is performed using the least absolute shrinkage and selection operator to screen out characteristic genes from the core genes.
[0098] In one embodiment, 10-fold cross validation is used to screen the best diagnostic genes from the characteristic genes, and a model for predicting IA based on the best diagnostic genes is constructed.
[0099] In one embodiment, transcriptome data of subject samples of GSE122897 and GSE15629 in GEO are obtained, wherein GSE122897 is a training set and GSE15629 is a validation set.
[0100] In one embodiment, the screening thresholds for differentially expressed genes in the KLF6 high expression group and the KLF6 low expression group are: |log2FC|>0.1, FDR<0.05.
[0101] In one embodiment, the classifier includes a support vector machine, a random forest, or a decision tree.
[0102] In one embodiment, a method for predicting IA risk based on KLF6 comprises:
[0103] S101: Obtaining KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16;
[0104] S102: Input the gene expression data into a support vector machine classifier, and output the classification result of IA risk.
[0105] In one embodiment, a method for predicting IA risk based on KLF6 comprises:
[0106] S101: Obtaining KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16;
[0107] S102: Input the gene expression data into a random forest classifier, and output the classification result of IA risk.
[0108] In one embodiment, a method for predicting IA risk based on KLF6 comprises:
[0109] S101: Obtaining KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16;
[0110] S102: Input the gene expression data into a decision tree classifier, and output the classification result of IA risk.
[0111] In one embodiment, the classification result is an output of whether the subject is at risk of suffering from IA.
[0112] In one embodiment, the optimal diagnostic genes include NEDD9, NPTX1, PTP4A1, DUSP16.
[0113] In one embodiment, the data of the training set is used to build the model, and the data of the validation set is used to validate the model.
[0114] An embodiment of the present invention provides a computer-readable storage medium storing a program for executing the method for screening candidate drugs for treating IA based on KLF6 as described above.
[0115] An embodiment of the present invention provides a computer-readable storage medium storing a program for executing the method for predicting IA risk based on KLF6 as described above.
[0116] One aspect of the present invention provides an electronic device, comprising:
[0117] A memory, a processor and a computer program stored in the memory; the processor executes the computer program to implement the method for screening candidate drugs for treating IA based on KLF6 as described above.
[0118] An embodiment of the present invention provides an electronic device, comprising:
[0119] A memory, a processor and a computer program stored in the memory; the processor executes the computer program to implement the method for predicting IA risk based on KLF6 as described above.
[0120] An embodiment of the present invention provides a method for constructing an IA model, the method comprising administering a promoter of KLF6.
[0121] In one embodiment, the promoter promotes the expression of KLF6.
[0122] In one embodiment, the promoter includes a KLF6 overexpression vector or a KLF6 protein.
[0123] In one embodiment, the method further comprises administering H2O2 treatment or elastase treatment.
[0124] In one embodiment, the model has more severe disease features.
[0125] In one embodiment, the model is a cell model or an animal model.
[0126] An embodiment of the present invention provides an IA model constructed by the above-mentioned method for constructing an IA model.
[0127] In one embodiment, the IA model is a cell model.
[0128] In one embodiment, the cells are selected from VSMCs.
[0129] An embodiment of the present invention provides a method for regulating the immune microenvironment, which comprises administering a KLF6 regulating agent or administering MLT.
[0130] In one embodiment, when the agent is a promoter of KLF6, the proportion of mononuclear cells is reduced; CD4 + The proportion of T cells increased.
[0131] In one embodiment, the promoter promotes the expression of KLF6.
[0132] In one embodiment, the promoter includes a KLF6 overexpression vector or a KLF6 protein.
[0133] In one embodiment, when the agent is an inhibitor of KLF6, the proportion of mononuclear cells increases; CD4 + The proportion of T cells decreases.
[0134] In one embodiment, the inhibitor inhibits the expression level of KLF6.
[0135] In one embodiment, the inhibitor comprises a nucleic acid inhibitor or a small molecule inhibitor against KLF6.
[0136] In one embodiment, the nucleic acid inhibitor comprises an interfering RNA, a sgRNA, or an antisense oligonucleotide.
[0137] In one embodiment, the small molecule inhibitor comprises MLT.
[0138] In one embodiment, when MLT is administered, the proportion of mononuclear cells increases; CD4 + The proportion of T cells decreases.
[0139] An embodiment of the present invention provides a method for regulating the expression level of KLF6 by administering MLT.
[0140] In one embodiment, MLT inhibits the expression level of KLF6.
[0141] An embodiment of the present invention provides a method for inhibiting apoptosis of vascular wall cells, comprising administering MLT, or a specific inhibitor of KLF6.
[0142] In one embodiment, the specific inhibitor of KLF6 is selected from nucleic acid inhibitors against KLF6.
[0143] In one embodiment, the nucleic acid inhibitor comprises an interfering RNA, a sgRNA, or an antisense oligonucleotide.
[0144] In one embodiment, apoptosis of vascular wall cells is inhibited by inhibiting pro-apoptotic factors or promoting anti-apoptotic factors.
[0145] In one embodiment, the pro-apoptotic factor is selected from Bax and cleaved caspase-3; the anti-apoptotic factor is selected from Bcl-2.
[0146] An embodiment of the present invention provides a method of inhibiting inflammation, comprising administering MLT, or a specific inhibitor of KLF6.
[0147] In one embodiment, the specific inhibitor of KLF6 is selected from nucleic acid inhibitors against KLF6.
[0148] In one embodiment, the nucleic acid inhibitor comprises an interfering RNA, a sgRNA, or an antisense oligonucleotide.
[0149] In one embodiment, inflammation is inhibited by inhibiting inflammatory factors.
[0150] In one embodiment, the inflammatory factor is selected from IL-1β, IL-6, TNF-α.
[0151] An embodiment of the present invention provides a method of promoting inflammation, comprising administering a promoter of KLF6.
[0152] In one embodiment, the promoter promotes the expression of KLF6.
[0153] In one embodiment, the promoter includes a KLF6 overexpression vector or a KLF6 protein.
[0154] In one embodiment, inflammation is promoted by increasing inflammatory factors.
[0155] In one embodiment, the inflammatory factor is selected from IL-1β, IL-6, TNF-α.
[0156] An embodiment of the present invention provides the use of a reagent for detecting a biomarker in the preparation of a product for diagnosing IA, wherein the biomarker is selected from one or more of NEDD9, NPTX1, PTP4A1, and DUSP16.
[0157] In one embodiment, the biomarkers are selected from a combination of NEDD9, NPTX1, PTP4A1, DUSP16.
[0158] In one embodiment, the reagent for detecting a biomarker includes a reagent for detecting the level of biomarker mRNA or a reagent for detecting the level of biomarker protein.
[0159] In one embodiment, the reagents for detecting the biomarker mRNA level include oligonucleotide probes that specifically recognize the biomarker mRNA and primers that specifically amplify the biomarker mRNA.
[0160] In one embodiment, the reagent for detecting the level of a biomarker protein includes a binding agent that specifically binds to the biomarker protein; the binding agent includes but is not limited to a ligand or an antibody that binds to the protein.
[0161] An embodiment of the present invention provides a use of KLF6 in the preparation of a pharmaceutical composition for treating IA, wherein the pharmaceutical composition comprises an inhibitor of KLF6.
[0162] In one embodiment, the inhibitor comprises a nucleic acid inhibitor or a small molecule inhibitor against KLF6.
[0163] In one embodiment, the nucleic acid inhibitor comprises an interfering RNA, a sgRNA, or an antisense oligonucleotide.
[0164] An embodiment of the present invention provides the use of MLT in the preparation of a pharmaceutical composition for treating IA.
[0165] In one embodiment, the pharmaceutical composition for treating IA inhibits the tumor formation rate of IA.
[0166] In one embodiment, the pharmaceutical composition for treating IA promotes the proliferation of vascular wall cells.
[0167] In one embodiment, the pharmaceutical composition for treating IA inhibits apoptosis of vascular wall cells.
[0168] In one embodiment, the pharmaceutical composition for treating IA inhibits apoptosis of vascular wall cells by inhibiting apoptotic factors and promoting anti-apoptotic factors.
[0169] In one embodiment, the pharmaceutical composition for treating IA inhibits the levels of apoptosis factor Bax and cleaved caspase-3 proteins, and promotes the level of anti-apoptosis factor Bcl-2 protein.
[0170] In one embodiment, the pharmaceutical composition for treating IA improves the hypoxic state.
[0171] In one embodiment, the pharmaceutical composition for treating IA modulates
[0172] In one embodiment, the pharmaceutical composition for treating IA improves the immune microenvironment of vascular wall cells.
[0173] In one embodiment, the pharmaceutical composition for treating IA promotes the proportion of monocytes and / or reduces CD4 + The proportion of T cells.
[0174] In one embodiment, the pharmaceutical composition of the present invention as described above reduces inflammatory responses.
[0175] In one embodiment, the pharmaceutical composition reduces inflammatory response by reducing inflammatory factors, including IL-1β, IL-6 and TNF-α.
[0176] In one embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0177] In a specific embodiment, the expression status of KLF6 in IA and its role in the mechanism of IA formation were studied.
[0178] Data acquisition and preprocessing
[0179] The Gene Expression Omnibus (GEO) database was obtained (https: / / www.ncbi.nlm.nih.gov / geo / ) datasets GSE122897 and GSE15629, GSE122897 was used as the training set, and GSE15629 was used as the validation set. The gene expression profiles were annotated using the GPL platform annotation file. GSE122897 included 16 control samples, 21 unruptured and 22 ruptured IA samples; GSE15629 included 5 control samples, 6 unruptured and 8 ruptured IA samples.
[0180] Characterization analysis of KLF6
[0181] The data sets GSE122897 and GSE15629 were obtained to draw the expression box plots of KLF6 gene in control and IA, and the receiver operating characteristic curve (ROC) of KLF6 was analyzed using the pROC package. The area under the curve (AUC) represents the diagnostic value of KLF6. The data of the training set GSE122897 were obtained to analyze the expression of KLF6 in indicators such as rupture and non-rupture, different ages, and different genders.
[0182] IA microenvironment analysis
[0183] The CIBERSORT algorithm was used to calculate the proportion of immune cells in each sample based on gene expression. The 22 immune cells in IA were compared using the Wilcoxon.test, and the percentage of different immune cells in each sample was displayed in a stacked column chart. In addition, the correlation between differential immune cells and KLF6 was calculated using the Pearson correlation coefficient method.
[0184] Differentially expressed gene analysis
[0185] Based on the expression data of KLF6 in the GSE122897 dataset, the IA samples were divided into samples with high KLF6 expression and samples with low KLF6 expression according to the median of KLF6 expression. The expression data of KLF6 in the training set GSE122897 were analyzed using the “limma” package in R, and the differentially expressed genes (DEGs) between the high and low KLF6 expression groups with |log2FC|>1 and FDR<0.05 were obtained.
[0186] Weighted co-expression network analysis
[0187] The R package “WGCNA” was used to perform co-expression network analysis on all genes and construct a scale-free gene co-expression network.
[0188] The 43 IA sample data were clustered using the average linkage method in the “hclust” function to detect outliers. 70 was selected as the height of the cutting tree to remove outliers. Then, the “pickSoftThreshold” function was used to select an appropriate soft threshold (β=6) to construct a scale-free topology. The height was set to 0.90, and the minimum number of genes in the module was set to 150. Then, the adjacency matrix was calculated based on the kernel value, and the adjacency matrix was converted into a topological overlap matrix (TOM) and a corresponding dissimilarity matrix (1-TOM). Genes with similar expression patterns were clustered together, and the modules were divided according to the “cutreeDynamic” function with default parameters. Since the modules identified by the dynamic tree cutting algorithm may be similar, they were merged by truncating them at a height of 0.25. The phenotypic data representing the high and low KLF6 expression groups were extracted, and their correlation with the WGCNA module was analyzed. Finally, the hub modules associated with the high and low KLF6 expression groups were selected.
[0189] Core gene identification
[0190] Candidate core genes were selected based on the module connectivity of each gene in the hub module related to KLF6 high and low grouping obtained by WGCNA analysis and the KLF6 high and low grouping relationship. Module connectivity is defined as the absolute value of Pearson correlation between genes (MM). The KLF6 high and low grouping relationship is defined as the absolute value of Pearson correlation between each gene and KLF6 high and low grouping (GS). Genes with |MM|>0.6 and |GS|>0.4 in the hub module were selected as key genes; the intersection genes of key genes and differential genes were defined as core genes.
[0191] Drug prediction and molecular docking
[0192] Based on the DGIdb (https: / / dgidb.org / ) database, we screened out drugs related to core genes that differed between disease and control groups, hoping to provide a new perspective for disease diagnosis, treatment and research.
[0193] Molecular docking was performed between some drugs and genes. Low binding energy is the basis for stable binding between molecules. The purpose of molecular docking is to find the best binding position when the binding energy is lowest. The three-dimensional structure file of the target protein as a receptor was retrieved and downloaded from RCSB PDB (http: / / www.rcsb.org / pdb / home / home.do), and the three-dimensional structure file of the drug was downloaded from pubchem (https: / / pubchem.ncbi.nlm.nih.gov / ). Proteins and drug molecules were hydrogenated and other pre-processed in AutoDockTools, and then molecular docking calculations were performed. The docking results used binding energy as a reference to screen the most active ligand molecules and target genes. A binding energy less than 0 means that the ligand and receptor can bind spontaneously. The smaller the binding energy, the more stable the binding between the ligand and the receptor, and the binding activity is better when the binding energy is less than -5.0kJ / mol.
[0194] Feature selection and model building
[0195] Machine learning algorithm modeling was used to identify the most suitable mRNA biomarkers for IA prediction.
[0196] First, the least absolute shrinkage and selection operator of the R software "glmnet" package was used for LASSO regression analysis to screen out characteristic genes from the core genes. Secondly, the importance of each gene selected by LASSO was ranked from large to small according to the value of mean decreasing precision using the random forest algorithm in the R package "random Forest". Finally, random forest ("random Forest") and support vector machine ("e1071") classification models were established respectively. The diagnostic ability of the model and the predictive ability of each gene biomarker were evaluated according to the ROC curve.
[0197] Clinical sample validation
[0198] Clinical Cases
[0199] Samples were obtained from 13 patients with clinically diagnosed IA and 13 normal people. All patients signed informed consent, and this study was approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University.
[0200] Inclusion criteria: (1) The diagnosis of IA is in accordance with the diagnosis and treatment guidelines. (2) Age >18 years. (3) No treatment was received within 1 month before enrollment. (4) Informed consent was obtained from the patient.
[0201] Exclusion criteria: (1) Patients with autoimmune diseases. (2) Patients with other diseases that affect the body's immune response, inflammatory response, etc. (3) Patients with other brain diseases. (5) Pregnant or lactating women. (6) Patients who have undergone surgery or other treatments.
[0202] Quantitative PCR assay for KLF6
[0203] Total RNA was extracted from cells using TRIzon Reagent, and the concentration and content of total RNA were detected by Thermo Nano Drop 2000. The integrity of total RNA was detected by Agilent-2100 sulfate polyacrylamide gel electrophoresis. Evo M-MLV reverse transcription reagent was used to reverse the RNA into cDNA. The expression level of KLF6 was detected by RT-qPCR using GADPH as the internal reference gene. SYBR Green Pro Taq HS Mix (Takara Bio, Japan) was used for qPCR. The procedure of the reaction system was as follows: incubation at 95°C for 30 s, 95°C for 40 cycles for 5 s, and 60°C for 30 s for a total of 3 times. The relative expression was determined using the 2-ΔΔct method. P < 0.05 was considered statistically significant.
[0204] Enzyme-linked immunosorbent assay for ET-1 and VWF
[0205] Endothelin-1 (ET-1) and von Willebrand factor (vWF) in plasma are indicators of endothelial cell function. They are called markers of endothelial function, and abnormalities in their circulating levels indicate endothelial dysfunction.
[0206] Serum related indicators were detected by ELISA kit. After centrifugation of blood samples, endothelin-1 (ET-1) and von willebrand factor (vWF) were checked according to the kit instructions. Balance the reagents, dilute with concentrated washing solution, and set aside. Add samples, seal the plate, incubate, wash, and pat dry. Add enzyme, incubate, and wash. Add color developer to develop color, add stop solution to stop the reaction, and read the OD value at a wavelength of 450nm.
[0207] Western Blot Detection of KLF6
[0208] Proteins were separated by 10% polyacrylamide gel, electroblotted on polyvinylidene difluoride membranes, and then blocked with 5% skim milk powder. After incubation with KLF6 (1:800) and GAPDH (1:50000) at 4°C overnight, horseradish peroxidase-labeled secondary antibodies (1:5000) were added, and finally quantified by ECL incubation and quantitative analysis using Image J software.
[0209] Statistical analysis
[0210] R was used for statistical analysis. Two-tailed t-test was used to calculate individual P values. Stouffer test was used to merge individual P values and correct for multiple comparisons. Benjamini and Hochberg method was used to obtain false discovery rate. Independent sample t-test was used for differential expression analysis between groups. P<0.05 was considered statistically significant.
[0211] result
[0212] Datasets GSE122897 and GSE15629 plot the expression of KLF6 gene in control and IA. Figure 3 As shown in the figure, KLF6 was significantly highly expressed in IA in both datasets, and the AUC values of the ROC curve were 0.701 and 0.829, respectively. At the same time, the differential expression of KLF6 in different clinical indicators was analyzed and compared in the validation set dataset, and the results showed that there was no significant difference in KLF6 between ruptured and unruptured IA, age, and gender.
[0213] CIBERSORT algorithm analyzes the microenvironment and KLF6, CD4 in the training set + T cells and macrophages were significantly different in the KLF6 high and low expression groups. Macrophages were negatively correlated with KLF6 (r = -0.46), while CD4 + T cells and KLF6 were positively correlated (r=0.37).
[0214] Using WGCNA analysis, the soft threshold β=6 was used to construct a scale-free network, and the minimum number of genes in the module was set to 150. A total of 19 modules were obtained, and the modules with dissimilarity <25% were merged. Finally, 16 modules were determined, and the KLF6 high and low expression groups were extracted as phenotypic data, and their association with the WGCNA modules was analyzed. Three hub modules related to the KLF6 high and low expression groups were selected.
[0215] Genes in the three hub modules were extracted. According to |MM|>0.6 and |GS|>0.4, a total of 396 genes were associated with the KLF6 high and low expression groups. These 396 genes were intersected with the differentially expressed genes to obtain 76 core genes.
[0216] The differential expression analysis of 76 core genes showed that 22 genes were significantly different between control and IA (KLF6, ZBTB21, GPRC5A, NEDD9, DUSP5, NFIL3, ITPRIP, ABL2, C8orf4, EIF2AK3, EMP1, PTP4A1, EIF4A3, MYC, UAP1, RCAN1, UGCG, TRIB1, SLC41A1, XIRP1, CD70, NPTX1). The 22 genes were put into the DGIdb database to query drugs, among which ABL2, EIF2AK3, EMP1, PTP4A1, MYC, UGCG, and CD70 were found to have related drugs. Molecular docking was performed on the queried drugs, and it was found that melatonin MLT had the best conformation with the target protein.
[0217] After analyzing the 76 intersection genes with the LASSO regression model, a total of 8 genes were selected. The 8 genes were ranked according to the average decreasing accuracy. The results of 10-fold cross-validation showed that the accuracy was highest when the number of genes was 4. Four genes were selected as the best diagnostic genes (NEDD9, NPTX1, PTP4A1, DUSP16), and then the 4 best diagnostic genes were used to establish a classification model through the random forest package, support vector machine and decision tree. The AUC of the support vector machine model (SVM) was 0.834, the sensitivity was 83.7%, and the specificity was 81.2%. The AUC of the random forest model (RF) was 0.791, the sensitivity was 93.0%, and the specificity was 62.5%. The results are as follows Figure 4 As shown, the individual AUCs of these four genes are smaller than those of the SVM and RF models. The accuracy of the model was verified in the independent data set GSE15629. In GSE15629, the AUC value of the SVM model was 0.914, and the AUC value of the RF model was 0.914. The individual AUCs of these four genes in the validation group were also smaller than those of the SVM and RF models.
[0218] In the training set GSE122897 and the validation set GSE15629, NEDD9 and PTP4A1 were significantly overexpressed, and NPTX1 was significantly underexpressed.
[0219] The results of fluorescence quantitative PCR were as follows Figure 5 As shown in the figure, the expression of KLF6 in IA patients was significantly higher than that in the normal group (P<0.05).
[0220] ELISA test results Figure 6 As shown in the figure, compared with the normal group, the serum ET-1 and vWF concentrations in the IA group were significantly increased (P<0.001).
[0221] The results of WB experiments are as follows Figure 7As shown in the figure, compared with the normal group, the expression of KLF6 protein in the IA group was significantly increased (P < 0.001).
[0222] In a specific embodiment, the effect of MLT-mediated KLF6 on HBVSMC cells in vitro was studied by constructing a stable KLF6 gene knockout cell.
[0223] After HBVSMC cells were revived and passaged, they were grouped;
[0224] Lentivirus infection: Replace the original culture medium with 2 ml fresh culture medium containing 40 μL polybrene, add 2.7 μL KLF6 knockout and 4 μL NC virus suspension at an MOI value of 10, and incubate at 37°C. Continue to culture and observe the infection efficiency. When the infection rate is greater than 40%, the infection is complete.
[0225] Construction of stable transfected strains: Screen with puromycin until the proportion of fluorescent cells observed under a microscope is more than 90%. Verification: Fluorescence quantitative PCR verification, select the lentivirus with the highest knockdown efficiency for the following cell experiments. When the number of cells is sufficient and the condition is good, digest the cells with trypsin, resuspend them in complete culture medium into a cell suspension, and count the cells. Plate, 6-well plate, 2×10 5 / well, placed in a 37℃ 5% CO2 cell culture incubator for culture. After the cells adhered to the wall, they were divided into 6 groups: control group (blank cells), H2O2 treatment group, H2O2+Melatonin, H2O2+pcDNA-NC, H2O2+pcDNA-KLF6, H2O2+pcDNA-KLF6+Melatonin. H2O2 treatment: After the sh-NC and sh-KLF6 stable transfectants were successfully constructed, the following groups were set up: control group (blank cells), H2O2 treatment group, H2O2+sh-NC, H2O2+sh-KLF6. Normal cells and stable transfectants were cultured at 1×10 5 / well in a 12-well plate. About 24 hours after the cells adhered to the wall, 180μM H2O2 was added to the H2O2 treatment group, H2O2+sh-NC, and H2O2+sh-KLF6 groups for 6 hours, and the control group (blank cells) was treated with the corresponding volume of PBS. After the H2O2 stimulation, the cells were collected for subsequent experimental detection. H2O2+Melatonin: On the basis of the H2O2 group, MLT was added at a dose of 100μM for 6 hours. H2O2+pcDNA-KLF6+Melatonin: On the basis of the H2O2+sh-KLF6 group, MLT was added at a dose of 100μM for 6 hours.
[0226] Determination of KLF6 content
[0227] Detection of KLF6 mRNA content by fluorescence quantitative PCR
[0228] TRIzon Reagent (CW0580S) was used to extract total RNA from cells, and the integrity of total RNA was detected by Agilent-2100 sulfate polyacrylamide gel electrophoresis. The remaining steps were the same as the fluorescent quantitative PCR experiment in Example 1.
[0229] Western Blot analysis of KLF6 protein content
[0230] Extract total cell protein and perform concentration determination: rinse cells, mix cell culture bottles, centrifuge, ice bath, centrifuge, protein concentration detection: BCA protein quantitative method to determine protein concentration. The remaining steps are equivalent to Western Blot determination of KLF6 protein content in Example 1.
[0231] Cell proliferation assay
[0232] MTT experiment: When the cells that have been revived and subcultured are judged to have sufficient cell number and viability, they are enzymatically resuspended into a cell suspension and inoculated in a 96-well plate. The number of cells added is determined according to the proliferation rate. The cells are cultured for 24 hours. Different concentrations of H2O2, 30μM, 90μM, and 180μM, are added to stimulate the cells. The MTT solution is cultured for 4 hours. The cells are obtained by centrifugation. DMSO dissolves the crystals. The absorbance value is measured by a microplate reader.
[0233] Clone formation experiment: When the cells that have been revived and subcultured are judged to have sufficient cell number and vitality, enzymatically resuspend them into cell suspension and count them. Inoculate them in a 6-well plate, with 1000 cells per well, and set up 3 replicate wells in each group. Add 30μm, 90μm, and 180μm H2O2 at different concentrations to stimulate the cells for drug treatment. Transfection treatment. Culture for 14 days and closely observe the cell status. Take pictures and wash the cells. Fix the cells with 4% paraformaldehyde and wash the cells with PBS. Stain the cells with crystal violet stain. Wash the cells, dry them, take pictures, and count them.
[0234] Cell apoptosis assay
[0235] AnnexinV-PE / 7-AAD apoptosis detection kit (Meilunebio, MA0429) was used, and the rest of the experimental instruments and reagents were the same as those in the cell proliferation experiment. Strictly follow the instructions of the AnnexinV-PE / 7-AAD apoptosis detection kit. As mentioned above: complete cell infection and apoptosis induction. After dilution and trypsin digestion, add cell culture medium, centrifuge, wash, and centrifuge in a centrifuge tube to complete two cycles, and finally collect the cell pellet. Resuspend the cells in Binding buffer working solution, add cell suspension, AnnexinV-PE, and 7-AAD to a new tube, mix well, and incubate for 15 minutes. Flow cytometry detection, and analysis with software such as CellQuest.
[0236] Western Blot detection of Bcl-2, Bax and cleaved caspase-3 expression
[0237] Western Blot was used to determine the levels of Bcl-2, Bax and cleaved caspase-3 proteins using the same method as above.
[0238] Immune microenvironment related index experiments
[0239] Flow cytometry was used to detect monocytes (CD14 + HLA-DR + )、Treg(CD4 + FOXP3 + ): Add the corresponding fluorescently labeled flow cytometry antibody to the cell suspension and incubate. Centrifuge at 400g for 5min, discard the supernatant, add PBS, suspend the cells, centrifuge at 400g for 5min, discard the supernatant, and repeat once. Add 250μL of Foxp3 / perm solution, mix well, incubate at 4℃ in the dark for 20min, centrifuge at 400g and discard the supernatant. Add fluorescently labeled Foxp3 flow cytometry antibody, incubate at 4℃ in the dark for 30min. Centrifuge at 400g for 5min, discard the supernatant, add PBS, suspend the cells, centrifuge at 400g for 5min, discard the supernatant, and repeat once. Add 200μL of PBS to resuspend the cells into a single cell suspension and analyze on a flow cytometer.
[0240] Enzyme-linked immunosorbent assay for inflammation-related markers
[0241] Serum related indicators were detected by ELISA kit. After centrifugation of blood samples, IL-1β, IL-6, and TNF-α were checked according to the kit instructions. Balance reagents, dilute with concentrated washing solution, and set aside. Add samples, seal the plate, incubate, wash, and pat dry. Add enzyme, incubate, and wash. Add colorimetric reagent to develop color, add stop solution to stop the reaction, and read the OD value at a wavelength of 450nm.
[0242] result
[0243] Fluorescence quantitative PCR test results Figure 8 As shown, compared with the control group, the mRNA expression level of KLF6 in the H2O2 treatment group was significantly increased; compared with the H2O2 group, the mRNA expression level of KLF6 in the H2O2+Melatonin group was significantly decreased; compared with the H2O2 treatment group, the mRNA expression level of KLF6 in the H2O2+pcDNA-NC group had no significant change; compared with the H2O2+pcDNA-NC group, the mRNA expression level of KLF6 in the H2O2+pcDNA-KLF6 group was significantly increased; compared with the H2O2+pcDNA-KLF6 group, the mRNA expression level of KLF6 in the H2O2+pcDNA-KLF6+Melatonin group was significantly decreased; (***P<0.001, ns P>0.05).
[0244] Western Blot results Fig. 9 As shown, compared with the control group, the expression of KLF6 protein in the H2O2 treatment group was significantly increased; compared with the H2O2 group, the expression of KLF6 protein in the H2O2+Melatonin group was significantly decreased; compared with the H2O2+pcDNA-NC group, the expression of KLF6 protein in the H2O2+pcDNA-KLF6 group was significantly increased; compared with the H2O2+pcDNA-KLF6 group, the expression of KLF6 protein in the H2O2+pcDNA-KLF6+Melatonin group was significantly decreased (***P<0.001).
[0245] The results of MTT and clone formation assays are shown in Fig.10 As shown: KLF6 promotes the damage caused by H2O2, and Melatonin can reverse the damage caused by H2O2 and KLF6.
[0246] The results of flow cytometry apoptosis experiments were as follows Fig.11 As shown, KLF6 promotes cell apoptosis, while Melatonin inhibits cell apoptosis.
[0247] The results of Western Blot detection of Bcl-2, Bax and cleaved caspase-3 are shown in Fig.12 As shown, KLF6 promoted the expression of Bax and cleaved caspase-3 proteins and inhibited the expression of Bcl-2 protein; Melatonin inhibited the expression of Bax and cleaved caspase-3 proteins and promoted the expression of Bcl-2 protein.
[0248] The results of immune microenvironment related index detection are as follows Fig.13As shown, KLF6 reduces the proportion of monocytes and increases CD4 + T cell ratio; Melatonin promotes monocyte ratio and reduces CD4 + T cell ratio.
[0249] Inflammatory factor test results such as Fig.14 As shown, KLF6 promotes inflammation and Melatonin inhibits inflammation.
[0250] In a specific embodiment, MLT inhibits intracranial aneurysm formation in mice
[0251] Animal origin
[0252] 33 C57BL / 6 male mice, aged 5-6 weeks, weighing 18-22g were selected. Provided by Spaif. All mice were raised in single cages in the First Affiliated Hospital of Anhui Medical University. The feeding conditions were: temperature: 24-26℃, humidity 70%. They were numbered 1-33 according to their weight, with 6 mice in each group. There were 3 more mice in each group, including the model group, model group + solvent, and model group + Melatonin. A total of 33 mice were randomly divided into 4 groups according to the random number table. Group A had 6 mice as the blank control group, Group B had 9 mice as the IA model group, Group C had 9 mice as the model group + solvent, and Group D had 9 mice as the model group + Melatonin. After the final modeling, the dead mice were removed, and there were 7 mice in each group.
[0253] Animal modeling
[0254] The animals were adaptively fed for 7 days. The elastase-induced aneurysm model was used to establish the IA model. The specific method is as follows:
[0255] Place the mouse in an anesthesia induction box, and after inducing anesthesia with 5% isoflurane, switch to a breathing mask to maintain anesthesia with 1.5% isoflurane (gas flow rate maintained at 1L / min). Renal pedicle ligation: Use abdominal hair to prepare the skin, disinfect the skin on the left side of the abdomen with alcohol, and make a 1.5cm straight incision to expose the subcutaneous tissue, muscle, and peritoneum at one time to enter the abdominal cavity. After the surgeon finds the kidney, lift the kidney out of the incision, distinguish the surrounding greater omentum, and push it back into the abdominal cavity, find the renal hilum, and ligate the renal pedicle. If the kidney is seen to be dark red and congested, it proves that the ligation is successful, return the kidney, suture, and disinfect the incision. Left carotid artery ligation: Disinfect the skin of the surgical area of the neck with alcohol, make a 1.5cm straight incision, and expose the subcutaneous tissue, fat, superficial fascia, platysma, deep cervical fascia, and anterior tracheal muscle in turn, through the front edge of the left sternocleidomastoid muscle, deep cervical fascia, and sternocleidomastoid muscle until the carotid sheath is found. Then separate the common carotid artery and ligate the common carotid artery. Suture and disinfect the incision. After surgery, the mice were placed on a 37°C heating pad and returned to the cage after awakening from anesthesia. After surgery, the mice were given 1% high-salt drinking water and normal mouse food, and the mice were closely observed. After one week of feeding under normal conditions, the model group was given a cross-cistern stereotaxic injection of elastase.
[0256] Stereotaxic injection: After intraperitoneal injection of 3.3ml / kg of 10% chloral hydrate solution to anesthetize the mouse, fix the mouse in a supine position with a stereotaxic instrument, prepare the hair on the head, disinfect the head skin with alcohol, make a longitudinal incision of about 1cm, wipe the adhesion tissue on the top of the skull with a cotton swab, and find the bregma point as the origin. The injection point coordinates are 2.5mm behind the bregma point, 1.0mm to the right, and 5mm deep. After positioning, drill a hole in the skull, draw 5μl (50mU) with a microsyringe, insert the needle to a depth of 5mm, and adjust the injection pump speed to 0.5μl / min for injection. After the injection is completed, stop the needle in the skull for two minutes and then slowly withdraw the syringe. Suture the skin and put it back in the cage after waking up from anesthesia. After surgery, give 1% high-salt drinking water and normal mouse food, and closely observe the status of the mice.
[0257] Three days after surgery, 40,000 U of penicillin was injected intramuscularly to prevent wound infection.
[0258] Drug administration
[0259] Mice in the postoperative model + Melatonin group were intraperitoneally injected with MLT at a dose of 15 mg / kg, twice a week for 4 weeks;
[0260] Mice in the postoperative model+solvent group were intraperitoneally injected with an equal volume of normal saline twice a week for 4 weeks;
[0261] The mice in the other groups received no other treatment.
[0262] Tumor formation rate and angiographic examination
[0263] Bromophenol blue gelatin perfusion
[0264] ① Add 20% gelatin to 2mg / ml bromophenol blue solution to prepare bromophenol blue gelatin perfusion solution, and place it in the refrigerator for later use.
[0265] ②After 4 weeks of medication, do not drink or eat for 1 day.
[0266] ③Preheat the saline solution and perfusion solution, connect the infusion set and keep them ready for use.
[0267] ④ Perfusion of normal saline: Three mice were randomly selected from the control group and four mice were randomly selected from each of the other groups. They were anesthetized by intraperitoneal injection of chloral hydrate. The heart and atrial appendage were exposed in turn in the supine position, and blood was collected. The right atrial appendage was cut open, and 3 mL of normal saline was perfused through the left ventricle. The perfusion was complete when the liver turned khaki in color.
[0268] ⑤ Bromophenol blue gelatin perfusion: Repeat ④ to complete the bromophenol blue gelatin perfusion. When the perfusion fluid is seen flowing out of the right atrial appendage and the extremities, lips and ears of the mouse appear blue, it indicates that the perfusion is sufficient.
[0269] ⑥ Sampling: Wrap the perfused mice with gauze and place them in a clean box. After placing them in a 4°C refrigerator for 5 minutes, remove the head of the mice, take out the whole brain and cerebellum, take pictures under a stereoscope, observe and record the tumor formation rate. IA tumor assessment criteria: The basilar artery diameter is used as the reference standard in this study. IA tumor assessment criteria: The dilation degree of the IA lesion vessel diameter exceeds 1.5 times the reference basilar artery vessel diameter.
[0270] ⑦ Each group of 3 mice was intraperitoneally injected with 10% chloral hydrate at a dose of 3.3 mL / kg. After anesthesia, the chest was opened, the right atrial appendage was cut open, and 3 mL of normal saline was perfused from the left ventricle. When the liver turned into a yellowish brown color, it proved that the perfusion was complete. The brain tissue was removed and fixed with 4% paraformaldehyde for subsequent detection.
[0271] Tissue paraffin embedding, sectioning, and staining
[0272] ① Fixation: Take the brain tissue and fix it in a mixture of 1% paraformaldehyde and 2% glutaraldehyde for 24 hours.
[0273] ② Dehydration: alcohol gradient dehydration, 75% alcohol dehydration for 4h, 85% alcohol dehydration for 2h, 90% alcohol dehydration for 1.5h, 95% alcohol dehydration for 1h, anhydrous ethanol I dehydration for 0.5h, anhydrous ethanol II dehydration for 0.5h.
[0274] ③ Transparency: Soak in anhydrous ethanol and xylene in a ratio of 1:1 for 10 minutes, soak in xylene I for 10 minutes, and soak in xylene II for 10 minutes.
[0275] ④ Wax immersion: immerse in 3 tanks of wax at 60℃, immerse in paraffin I for 1 hour, immerse in paraffin II for 1 hour, immerse in paraffin III for 1 hour.
[0276] ⑤Embedding: Wrap the tissue blocks in the above ④ in paraffin blocks.
[0277] ⑥ Slicing and baking: Slice the tissue block in ⑤ using a biological tissue paraffin slicer and bake in a 60℃ oven for 3h.
[0278] Hematoxylin-eosin staining
[0279] ① Paste and bake: Take out the wax sheet, pour out the excess water, bake the sheet in the oven for 15 minutes, and then dewax.
[0280] ②HE staining: Use a fully automatic HE stainer (Leica Autostainer XL) for staining.
[0281] ③ Dehydrate and seal the slides, observe under a microscope and collect images. Basophilic structures are stained blue-purple, and eosinophilic structures are stained pink.
[0282] TUNEL staining
[0283] ① Paste and bake: Take out the wax sheet, pour out the excess water, bake the sheet in the oven for 15 minutes, and then dewax.
[0284] ② Permeabilization: Use an immunohistochemistry pen to draw a circle around the tissue, add diluted Proteinase K solution, incubate, and wash with PBS.
[0285] ③ Add reaction working solution, incubate: counterstain nuclei, dehydrate and seal, observe under a microscope and collect images. Blue represents cell nuclei and red represents apoptotic cells.
[0286] ④Statistical analysis: Aipathwell software automated image analysis. Evaluation indicators: Fluorescence single-label positive cell number analysis, red positive rate (Red Positive Cells%) = total number of red positive cells / total number of cells; Red Positive Cells Density (Red Positive Cells Density, number / 10 4 Red mean optical density = red light IOD / red light positive pixel area.
[0287] KLF6 expression level determination
[0288] Detection of KLF6 mRNA expression level by fluorescence quantitative PCR
[0289] Vascular tissues of the skull base of mice were obtained. Total RNA was extracted from the vascular tissues using TRIzon reagent and reversed to cDNA using Evo M-MLV reverse transcription reagent. The expression level of KLF6 was detected by RT-qPCR using GADPH as the internal reference gene. SYBR Green Pro Taq HS Mix (was used for qPCR. The procedure of the reaction system was as follows: incubation at 95°C for 30 s, 95°C for 40 cycles for 5 s, and 60°C for 30 s for a total of 3 times. The relative expression was determined using the 2-ΔΔct method. P < 0.05 was considered statistically significant.
[0290] Immunohistochemical determination of KLF6 expression
[0291] ① After the sections are dewaxed, antigen repair: 0.01M Tris-EDTA repair solution is placed in a beaker for 15 minutes. After natural cooling, take out the slides and rinse with TBS 3 times, 3 minutes each time.
[0292] ② Block endogenous peroxidase: Add 3% hydrogen peroxide onto the sliced tissue to block endogenous peroxidase, incubate at room temperature for 15 minutes, and rinse with TBS three times, each time for 3 minutes.
[0293] ③ Serum blocking: wipe the slide dry with absorbent paper, draw circles around the tissue with an immunoblot brush, add diluted normal goat serum, and block at room temperature for 30 minutes to reduce nonspecific staining.
[0294] ④ Add primary antibody: shake off excess liquid, do not wash, then add diluted primary antibody dropwise, and incubate overnight in a 4°C refrigerator.
[0295] ⑤ Add enzyme-labeled secondary antibody: Rinse the sections with TBS 3 times, 3 minutes each time, dry the sections with absorbent paper, add HRP-labeled goat anti-rabbit / mouse secondary antibody, and incubate at 37°C for 30 minutes.
[0296] ⑥DAB color development: Rinse the sections with TBS 4 times, 3 minutes each time, shake off the TBS solution, wipe the sections dry with absorbent paper, add freshly prepared DAB color development solution (dilute solution C 50 times with solution B in the immunochromogenic reagent) to each section, observe under a microscope, the positive signal is brown or tan, rinse the sections with deionized water to stop color development when it feels okay.
[0297] ⑦Re-staining: Re-stain with Mayer's hematoxylin for 2 minutes, then use TBS to fully turn blue.
[0298] ⑧ Dehydration: After rinsing the slices in water, place them in 70% alcohol-80% alcohol-90% alcohol-95% alcohol-anhydrous ethanol I-anhydrous ethanol II-xylene I-xylene II in sequence for dehydration and transparency. Place them in each reagent for 5 minutes, and finally air-dry the slices in a fume hood.
[0299] ⑨ Sealing: Drop neutral gum next to the tissue, and then cover it with a coverslip. Lay one side flat first, and then gently put down the other side to avoid bubbles. Place the sealed slices flat in a fume hood to dry.
[0300] ⑩ Microscopic examination and photography: The dried slices can be observed or images can be collected under a microscope.
[0301] Result determination: Use PBS as blank control. Observe the immunohistochemical staining pictures under a microscope. Positive indicator: KLF-6 protein is observed as brown-yellow particles in the cell membrane and cytoplasm. Negative indicator: No colored particles are observed in the cell membrane and cytoplasm.
[0302] Western Blot was used to detect the expression levels of NFIL3, HIF-1α, TIPARP, Bcl-2, Bax and cleaved caspase-3.
[0303] Proteins were separated by 10% polyacrylamide gel, electroblotted on polyvinylidene difluoride membranes, and then blocked with 5% skim milk powder. Immunoreaction: primary antibody incubation (Bcl-2, Bax, Cleaved caspase-3, NFIL3, HIF-1ɑ, TIPARP, GAPDH), secondary antibody incubation (HRP-labeled goat anti-rabbit, HRP-labeled goat anti-mouse), washing. Finally, ECL incubation was used for quantification (Servicebio), and quantitative analysis was performed using Image J software.
[0304] Immune microenvironment related index experiments
[0305] ① Experimental mice were anesthetized and killed, and pre-cooled PBS was perfused through the heart to remove excess peripheral blood in the skull. The whole brain tissue was collected and the cerebellum was removed. Then it was placed in pre-cooled PBS to wash away impurities on its surface. The brain tissue was ground and filtered through a cell sieve with a pore size of 70μm to make a single cell suspension, which was centrifuged at 4℃, 2000r for 10min and the supernatant was discarded.
[0306] ② Use Percoll liquid gradient separation method to separate the target cells for later use. The specific method is as follows: First, the Percoll liquid stock solution is mixed with 10×PBS at a ratio of 9:1 to prepare a 100% Percoll working solution for the experiment. Use 100% Percoll working solution and 1×PBS at a ratio of 7:3 to prepare a 70% Percoll working solution. Resuspend the cells with 7mL 1×PBS, then add 3mL 100% Percoll working solution, blow and mix, which is a 30% Percoll working solution. First add 3mL of 70% Percoll working solution to a 15mL centrifuge tube, and then use a pipette to slowly add the 30% Percoll working solution to the 70% Percoll working solution, 4℃, 2000r, acceleration set to 3, deceleration set to 2, centrifuge for 25min. After centrifugation, a white cell layer can be seen between the interface of 30% and 70% Percoll working solutions. Use a pipette to draw 2-3 mL of the white cell layer into a new centrifuge tube, add 1×PBS, centrifuge at 4°C, 2000r, and wash the cells 3 times in preparation for staining.
[0307] ③Flow staining
[0308] The above-treated brain tissue single-cell suspension was repeatedly blown up and down with a pipette to fully mix the cells on the tube wall, and a blank control well was set up.
[0309] Staining: Monocytes: Add 1 μL of fluorescently labeled CD14 and IA / IE flow cytometry antibodies to each tube, pipette repeatedly to fully mix the antibodies and single cell suspension, and incubate at room temperature in the dark for 30 minutes. (Treg: Add 1 μL of fluorescently labeled CD4 flow cytometry antibodies to each tube, pipette repeatedly to fully mix the antibodies and single cell suspension, and incubate at room temperature in the dark for 30 minutes; place each tube in a centrifuge and centrifuge at 1700 rpm for 7 minutes.
[0310] Discard the supernatant, resuspend the cells with 250 μL of Flux and Perm (membrane permeabilization), mix thoroughly, add FOXP3 antibody, and incubate at room temperature in the dark for 20 minutes.
[0311] Each tube was added and placed in a centrifuge, centrifuged at 2200 rpm for 7 min, the supernatant was discarded, the cells were washed with 500 μL PBS, placed in a centrifuge again, centrifuged at 2200 rpm for 7 min, and the supernatant was discarded.
[0312] 500 μL PBS was added to each tube and the samples were tested on a flow cytometer.
[0313] Statistical analysis
[0314] SPSS 22.0 was used to analyze the data, and the results were expressed as mean ± standard deviation. Independent sample t-test and analysis of variance were used to analyze the sample comparisons between two groups and multiple groups. P < 0.05 was considered to be a statistically significant difference.
[0315] result
[0316] In this experiment, elastase was used to induce intracranial aneurysm models, which were divided into four groups: control group, model group, model + solvent group, and model + Melatonin group. The tumor formation of each group is shown in Table 1. After MLT treatment, the IA tumor formation rate was significantly reduced, and the difference was statistically significant (P < 0.05).
[0317] Table 1 Comparison of tumor formation rate in four groups of animals
[0318]
[0319] HE staining results Fig.15 As shown, Melatonin improves the thickness of the vascular wall to make it uniform and maintains the structural integrity of the vascular endothelium and elastic membrane.
[0320] TUNEL staining statistical results are shown in Fig.16 As shown, Melatonin can significantly inhibit the apoptosis of VSMC cells.
[0321] Fluorescence quantitative PCR test results Fig.17As shown, Melatonin can significantly reduce the expression level of KLF6.
[0322] Immunohistochemical staining results Fig.18 As shown, Melatonin can significantly reduce the protein level of KLF6.
[0323] Western blot results Fig.19 As shown, Melatonin significantly reduced the expression of NFIL3, HIF-1α, TIPARP, Bax and cleaved caspase-3 proteins, and significantly increased the expression of Bcl-2.
[0324] Inflammatory factor test results such as Fig. 20 As shown, melatonin inhibits inflammation by inhibiting inflammatory factors.
[0325] Immune microenvironment test results Fig.21 As shown in Figure 2, Melatonin can significantly increase the proportion of monocytes and reduce CD4 + T cell ratio.
[0326] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. A method for screening candidate drugs for treating IA based on KLF6, It is characterized in that The method comprises: obtaining a core gene related to KLF6, Obtain drugs related to core genes related to KLF6, wherein the drugs are candidate drugs for treating IA.
2. The method according to claim 1, It is characterized in that The method for determining the core genes includes obtaining sample sequencing data; The KLF6 expression data of IA samples were obtained from the sequencing data, and the samples were divided into two groups based on the expression of KLF6: KLF6 high expression group and KLF6 low expression group; Obtain differentially expressed genes between the KLF6 high expression group and the KLF6 low expression group; Co-expression network analysis was performed on the sequencing data of IA samples, and the KLF6 high expression group and KLF6 low expression group were extracted as phenotypic data to screen the hub module; Extract genes in the hub module, screen key genes based on module connectivity and KLF6 high and low grouping relationships, extract key genes, and differentially expressed genes in the KLF6 high expression group and the KLF6 low expression group, and screen core genes; Preferably, genes with module connectivity |MM|>0.6 and KLF6 high-low grouping relationship |GS|>0.4 are key genes; preferably, the method further comprises molecular docking of drugs related to the core genes related to KLF6 and proteins encoded by the core genes related to KLF6; Preferably, screening for drugs with good binding activity; Preferably, the drug comprises MLT; Preferably, before molecular docking, the protein and drug molecules are hydrogenated using AutoDockTools; preferably, the sequencing data of the IA samples are subjected to co-expression network analysis using WGCNA; Preferably, the KLF6-related core genes include KLF6, ZBTB21, GPRC5A, NEDD9, DUSP5, NFIL3, ITPRIP, ABL2, C8orf4, EIF2AK3, EMP1, PTP4A1, EIF4A3, MYC, UAP1, RCAN1, UGCG, TRIB1, SLC41A1, XIRP1, CD70, and NPTX1.
3. A method for predicting IA risk based on KLF6, It is characterized in that The method comprises: Obtaining KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16; Inputting the gene expression data into a classifier and outputting a classification result of IA risk; Preferably, the classifier includes a support vector machine, a random forest, or a decision tree; Preferably, the method for constructing the classifier includes: Obtaining sequencing data of subject samples; The KLF6 expression data of IA samples were obtained from the sequencing data, and the samples were divided into two groups based on the expression of KLF6: KLF6 high expression group and KLF6 low expression group; Obtain differentially expressed genes between the KLF6 high expression group and the KLF6 low expression group; Co-expression network analysis was performed on the transcriptome data of IA samples, and the KLF6 high expression group and KLF6 low expression group were extracted as phenotypic data to screen the hub module; Extract genes from the hub module and screen key genes based on module connectivity and KLF6 high and low grouping relationships; extract key genes and differentially expressed genes in the KLF6 high expression group and the KLF6 low expression group to screen core genes; Regression analysis was performed on the core genes to screen characteristic genes and construct a model to predict IA; Preferably, genes with module connectivity |MM|>0.6 and KLF6 high-low grouping relationship |GS|>0.4 are key genes; preferably, LASSO regression analysis is performed using the least absolute shrinkage and selection operator to screen characteristic genes from the core genes; Preferably, 10-fold cross validation is used to screen the best diagnostic genes and construct a model for predicting IA based on the best diagnostic genes.
4. Computer readable storage medium, It is characterized in that It stores a program, and the program executes the method according to any one of claims 1 to 2; or The device stores a program for executing the method according to claim 3.
5. A system, It is characterized in that The system comprises: Acquisition unit: Acquisition of KLF6-related core genes; Analysis unit: Analysis of drugs related to core genes associated with KLF6; Output unit: output candidate drugs for treating IA; or Acquisition unit: acquiring KLF6-related gene expression data of the subject; the genes include NEDD9, NPTX1, PTP4A1, and DUSP16; Analysis unit: Analyze the risks of IA; Output unit: outputs the classification results of IA risks.
6. Electronic equipment, It is characterized in that include: a memory, a processor and a computer program stored on the memory; The processor executes a computer program to implement the method according to any one of claims 1 to 2; or A memory, a processor and a computer program stored in the memory; the processor executes the computer program to implement the method according to any one of claim 3.
7. A method for constructing an IA model. It is characterized in that administration of promoters of KLF6; Preferably, the promoter promotes the expression of KLF6; Preferably, the promoter comprises a KLF6 overexpression vector or a KLF6 protein; Preferably, the method further comprises administering H 2 O 2 treatment or elastase treatment; Preferably, the model has more severe disease features; Preferably, the model is a cell model or an animal model.
8. The IA model constructed by the method according to claim 7.
9. Either of the following methods: 1) A method for regulating the immune microenvironment, It is characterized in that administration of a KLF6 regulating agent or administration of MLT; Preferably, when the agent is a promoter of KLF6, the proportion of monocytes is reduced; CD4 + The proportion of T cells increased; Preferably, the promoter promotes the expression of KLF6; Preferably, the promoter comprises a KLF6 overexpression vector or a KLF6 protein; Preferably, when the agent is an inhibitor of KLF6, the proportion of monocytes increases; CD4 + The proportion of T cells decreases; Preferably, the inhibitor inhibits the expression level of KLF6; Preferably, the inhibitor comprises a nucleic acid inhibitor or a small molecule inhibitor against KLF6; Preferably, the nucleic acid inhibitor comprises interfering RNA, sgRNA or antisense oligonucleotide; Preferably, the small molecule inhibitor comprises MLT; Preferably, when MLT is administered, the proportion of monocytes increases; and the proportion of CD4+ T cells decreases. 2) A method for regulating the expression level of KLF6, It is characterized in that Administer MLT; Preferably, MLT inhibits the expression of KLF6; 3) A method for inhibiting apoptosis of vascular wall cells, characterized by comprising administering MLT or a specific inhibitor of KLF6; Preferably, the specific inhibitor of KLF6 is selected from nucleic acid inhibitors against KLF6; Preferably, the nucleic acid inhibitor comprises interfering RNA, sgRNA or antisense oligonucleotide; Preferably, apoptosis of vascular wall cells is inhibited by inhibiting pro-apoptotic factors or promoting anti-apoptotic factors; Preferably, the pro-apoptotic factor is selected from Bax and cleaved caspase-3; the anti-apoptotic factor is selected from Bcl-2; 4) A way to suppress inflammation, It is characterized in that including administration of MLT, or a specific inhibitor of KLF6; Preferably, the specific inhibitor of KLF6 is selected from nucleic acid inhibitors against KLF6; Preferably, the nucleic acid inhibitor comprises interfering RNA, sgRNA or antisense oligonucleotide; Preferably, inflammation is inhibited by inhibiting inflammatory factors; Preferably, the inflammatory factor is selected from IL-1β, IL-6, TNF-α; 5) A method for promoting inflammation, characterized by administering a promoter of KLF6; Preferably, the promoter promotes the expression of KLF6; Preferably, the promoter comprises a KLF6 overexpression vector or a KLF6 protein; Preferably, inflammation is promoted by increasing inflammatory factors; Preferably, the inflammatory factor is selected from IL-1β, IL-6, and TNF-α.
10. Any of the following applications: 1) Application of reagents for detecting biomarkers in the preparation of products for diagnosing IA, It is characterized in that The biomarker is selected from one or more of NEDD9, NPTX1, PTP4A1, and DUSP16; Preferably, the biomarker is selected from the combination of NEDD9, NPTX1, PTP4A1, and DUSP16; preferably, the reagent for detecting the biomarker includes a reagent for detecting the mRNA level of the biomarker or a reagent for detecting the protein level of the biomarker; Preferably, the reagents for detecting the biomarker mRNA level include oligonucleotide probes that specifically recognize the biomarker mRNA and primers that specifically amplify the biomarker mRNA; Preferably, the reagent for detecting the level of a biomarker protein comprises a binding agent that specifically binds to the biomarker protein; 2) Use of KLF6 in the preparation of a pharmaceutical composition for treating IA, characterized in that the pharmaceutical composition comprises an inhibitor of KLF6; Preferably, the inhibitor comprises a nucleic acid inhibitor or a small molecule inhibitor against KLF6; Preferably, the nucleic acid inhibitor comprises interfering RNA, sgRNA or antisense oligonucleotide; 3) Application of MLT in the preparation of a pharmaceutical composition for the treatment of IA; Preferably, the pharmaceutical composition inhibits the tumor formation rate of IA; Preferably, the pharmaceutical composition inhibits the proliferation of vascular wall cells; Preferably, the pharmaceutical composition inhibits apoptosis of vascular wall cells; Preferably, the pharmaceutical composition inhibits the levels of apoptotic factor Bax and cleaved caspase-3 proteins, and promotes the levels of anti-apoptotic factor Bcl-2 protein; Preferably, the pharmaceutical composition improves hypoxia; Preferably, the pharmaceutical composition improves the immune microenvironment of vascular wall cells; Preferably, the pharmaceutical composition promotes the proportion of monocytes and reduces CD4 + The proportion of T cells; Preferably, the pharmaceutical composition reduces inflammatory response; Preferably, the pharmaceutical composition reduces the levels of inflammatory factors IL-1β, IL-6 and TNF-α.
